---
document_datetime: 2024-11-22 15:18:44
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/doptelet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: doptelet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.8606068
conversion_datetime: 2025-12-22 16:36:25.452929
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Doptelet

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0023            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 21/11/2024                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0021             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                    | 06/05/2024   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0019           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                             | 04/03/2024   |            | SmPC                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| R/0018              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                    | 14/12/2023   | 09/02/2024 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Doptelet in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Minor changes are implemented in the PI in line with the latest QRD template. The product is being removed from the additional monitoring list and therefore the statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information, preceded by an inverted equilateral black triangle, is also being removed from the summary of product characteristics and the package leaflet. |
| PSUSA/10779 /202205 | Periodic Safety Update EU Single assessment - avatrombopag                                                                                                                                                                                                                                                                                                 | 12/01/2023   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0017/G           | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms | 12/12/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| II/0015/G   | This was an application for a group of variations. B.I.d.1.a.2 - Stability of AS - Change in the re-test period/storage period - Extension of the retest period based on extrapolation of stability data not in accordance with ICH/VICH guidelines B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier               | 08/12/2022   | n/a        |                 |                           |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|---------------------------|
| IB/0016     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/10/2022   | n/a        |                 |                           |
| IA/0013     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/06/2022   | 08/06/2023 | Annex II and PL |                           |
|             | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.b - Change in the batch size (including batch | 05/01/2022   | n/a        |                 | IB/0012/G size ranges) of |

<div style=\"page-break-after: always\"></div>

|                     | down to 10-fold B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |                                  |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10779 /202105 | Periodic Safety Update EU Single assessment - avatrombopag                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/12/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                          |
| IB/0010             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                           | 22/07/2021 | n/a        |                                  |                                                                                                                                            |
| PSUSA/10779 /202011 | Periodic Safety Update EU Single assessment - avatrombopag                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/06/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10779 /202005 | Periodic Safety Update EU Single assessment - avatrombopag                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/01/2021 | 31/03/2021 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10779/202005. |
| II/0004/G           | This was an application for a group of variations. Extension of indication to include the treatment of chronic immune thrombocytopenia (ITP) in adult                                                                                                                                                                                                                                                                                                                                                                         | 10/12/2020 | 18/01/2021 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Doptelet-H-C-4722-II- 0004-G'.                                                                      |

<div style=\"page-break-after: always\"></div>

|             | who are refractory to other treatments; consequently, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2 of the SmPC are updated. Additionally, the SmPC section 5.3 is updated with data from juvenile toxicity studies. Furthermore, an additional pack size of 30 tablets has been introduced with subsequent updates of sections 6.5 and 8 of the SmPC. The Package Leaflet and Labelling are updated in accordance. Version 2.7 of the RMP has also been updated. Furthermore, the PI is brought in line with the latest QRD template version 10.1. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |                        | patients modification   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------|
| T/0007      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/09/2020 | 09/10/2020 | SmPC, Labelling and PL |                         |
| IAIN/0005/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/08/2020 | 09/10/2020 | Annex II and PL        |                         |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |      |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/10779 /201911 | Periodic Safety Update EU Single assessment - avatrombopag                                                                                                                                                                                                                                                                                                                                                                                                                      | 11/06/2020 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0001             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                       | 04/12/2019 | 09/10/2020 | SmPC |                                   |